All In Biotech

Drug Trial Radar · NCT01863186

Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal

Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)

Last checked: Nov 20, 2026Latest source record: Mar 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 603 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

603

Actual

Start

Jun 2013

Primary completion

Nov 2014

Study completion Dec 2014

Sponsor

Lead sponsor
USWM, LLC (dba US WorldMeds)Industry
Sponsor type
Industry
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
May 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to look at the efficacy and safety for lofexidine hydrochloride, an alpha-2 adrenergic agonist under development for the treatment of acute withdrawal from short-acting opioids. The study takes place in 2 parts: a 7-day inpatient double-blind treatment portion where subjects will be randomly assigned to one of three doses of study medication (2.4 mg total daily dose of lofexidine, 3.2 mg total daily dose of lofexidine, or placebo) followed by an optional open-label treatment period where subjects will be inpatient or outpatient and receive lofexidine at variable dosing for up to an additional 7 days. The Investigator hypothesizes that subjects will achieve maximum treatment effect with tolerable side effects at the 3.2 mg total daily dose and that both the 3.2 mg and 2.4 total daily doses will show better efficacy over placebo in treating symptoms of acute opioid withdrawal.

Conditions

  • Opioid Dependence
  • Acute Opioid Withdrawal Syndrome

Interventions

  • Lofexidine HClDrug

    Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.

  • PlaceboDrug

    Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.

  • Open Label Lofexidine HCLDrug

    Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference Between the Overall Means From Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop) ScoresTime frame: Days 1 through 7

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Clovis, California

  • Site not named

    Escondido, California

  • Site not named

    San Diego, California

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Oak Park, Illinois

  • Site not named

    Lake Charles, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Flowood, Mississippi

  • Site not named

    St Louis, Missouri

  • Site not named

    Dayton, Ohio

  • Site not named

    Mason, Ohio

  • Site not named

    Austin, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    DeSoto, Texas

  • Site not named

    Orem, Utah

  • Site not named

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.